首頁 › 癌症（所有類型） › 德克薩斯州 › Austin
Austin, TX 的 癌症（所有類型） 臨床試驗
20 項針對 癌症（所有類型） 的研究正在 Austin（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
招募中2 期
- Texas Oncology-Austin North /ID# 279958, Austin
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
招募中3 期
- Texas Oncology, Austin
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
招募中1 期
- NEXT Oncology, Austin
Prospective Study to Assess a Diagnostic Aid for Cancer
招募中觀察性研究
- Premier Family Physicians, Austin
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
招募中2 期
- Dell Medical School, University of Texas at Austin, Austin
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
招募中1/2 期
- NEXT Oncology ( Site 1010), Austin
A Phase 1/1b Study of IAM1363 in HER2 Cancers
招募中1 期
- NEXT Oncology - Austin, Austin
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- USO - Texas Oncology, Austin
Project: Every Child for Younger Patients With Cancer
招募中觀察性研究
- Dell Children's Medical Center of Central Texas, Austin
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
招募中1 期
- Texas Oncology - Central South, Austin
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- Texas Oncology - Central/South Texas /ID# 268563, Austin
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
招募中2 期
- Texas Oncology - Central/South Texas /ID# 275154, Austin
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
招募中2/3 期
- Texas Oncology - South Austin /ID# 276033, Austin
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
招募中2 期
- Texas Oncology - Austin Central, Austin
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
招募中1 期
- GSK Investigational Site, Austin
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
招募中1 期
- NEXT Oncology Austin, Austin
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
招募中1/2 期
- NEXT Oncology, Austin
Beat Childhood Cancer Specimen Banking and Data Registry
招募中觀察性研究歡迎健康志工
- Dell Children's Blood and Cancer Center, Austin
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
招募中1/2 期
- NEXT Austin, Austin
A Study in Patients With Advanced Cancers
招募中1/2 期
- NEXT Oncology Austin, Austin
其他城市的 癌症（所有類型） 試驗
- Houston, TX121 項研究
- New York City, NY110 項研究
- Boston, MA86 項研究
- Los Angeles, CA73 項研究
- Nashville, TN65 項研究
- Philadelphia, PA59 項研究
- Durham, NC58 項研究
- Washington, DC58 項研究
- Chicago, IL51 項研究
- Seattle, WA49 項研究
- Atlanta, GA49 項研究
- Arlington, VA48 項研究
Austin 的其他研究
- 非小細胞肺癌30 項研究
- 肥胖症20 項研究
- 轉移性癌症19 項研究
- 大腸直腸癌19 項研究
- 心臟衰竭18 項研究
- 乳癌18 項研究
- 過重18 項研究
- 卵巢癌17 項研究
- 子宮內膜癌15 項研究
- 前列腺癌15 項研究
- 憂鬱症14 項研究
- 三陰性乳癌13 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。